In line with its mission, the Editorial Board of MedTvoiLokony makes every effort to provide reliable medical content supported by the latest scientific knowledge. The additional flag “Checked Content” indicates that the article has been reviewed by or written directly by a physician. This two-step verification: a medical journalist and a doctor allows us to provide the highest quality content in line with current medical knowledge.
Our commitment in this area has been appreciated, among others, by by the Association of Journalists for Health, which awarded the Editorial Board of MedTvoiLokony with the honorary title of the Great Educator.
The list of reimbursed drugs, effective from July 1, 2019, does not include one of the antidiabetic drugs called Diaprel MR 60 mg. According to the Polish Diabetes Association, this drug was used by almost 200. diabetics.
The Polish Diabetes Association (PSD) in its official position published on its website points out that from July 1, the price of the drug will increase by over 55% – from PLN 19 to about PLN 30!
«The decision made by the Ministry of Health may require about 200 additional jobs. visits by patients with type 2 diabetes, so far successfully treated with Diaprel MR 60 mg. Both in the opinion of experts and the Association – the necessity to modify the therapy, resulting from medically unjustified decisions to stop reimbursement, will have clearly negative consequences for patients’ health. ” At the same time, the association points out that “now patients can choose for themselves whether they want to buy the original drug or a cheaper equivalent. We do not understand why they would be deprived of this right. For a patient who has been successfully treated for several years, and often for several years, with a drug that he considers his own, such a change will not be understood or perceived as beneficial, ”points out the Polish Diabetes Association.
Already on June 21, at the time of publishing the draft list, it was widely protested by the community of patients and doctors. In a letter to the ministry, Anna Śliwińska, President of the Main Board of the Polish Diabetes Association, emphasized that it may have “serious consequences resulting from disrupting the continuity of the therapeutic process. The need to modify the therapy is most often associated with an additional specialist consultation and resetting the treatment. During this period, hundreds of thousands of patients will be at risk of losing glycemic control, with associated health deterioration and possible complications ». We wrote about the case here: Diabetics appeal to the minister of health – a new reimbursement list without the drug used for years by over 200 patients.
The Ministry of Health assured PAP that other drugs that work in the same way are available. “As part of the pharmacy list, a number of drugs containing the active ingredient Gliclazidum are reimbursed” – emphasizes the press spokesman of the Ministry. These are i.a. such drugs as Symazide in a dose of 60 mg and 30 mg, Salson (60 mg), Glicuron (60 mg), Gliclastad (30 mg), Gliclazide Zentiva (60 mg), Clazicon (60 mg and 30 mg) and Gliclastad (30 mg ). Sylwia Wądrzyk, Director of the Communication Office of the Ministry of Health, informed that the decision to reimburse Diaprel MR (Gliclazidum) in a dose of 30 mg was valid from January 1, 2019 for 3 years, while for a dose of 60 mg, it was valid from July 1, 2016 to 30 June 2019
Source: Polish Diabetes Association, PAP